EGFR and non-small cell lung carcinoma: To accomplish this, we chose LPIN1 among the candidate targets that were identified from a previously performed genome-wide RNAi screening assay and validated it as a key factor regulating gefitinib resistance in EGFR-mutant NSCLC cells.